Perbutylated-N -butyl-1-deoxynojiromycin (p-N -butyl-DNJ, SC-49483), an &alpha;-glucosidase-1 inhibitor, is a candidate anti-HIV agent targeted against viral glycoprotein processing in host cell endoplasmic reticulum. The potential toxicity of this compound was evaluated in Sprague-Dawley rats after 4, 13, or 26 wk of oral administration at doses ranging from 300 to 3,670 mg/kg/day. In these studies, the target organs of p-N -butyl-DNJ effects were thyroid gland, salivary gland, stomach, and pancreas. The most prominent histologic change in these organs was the presence of clear or lightly eosinophilic vacuoles in the cytoplasm of thyroid follicular cells, gastric chief cells, salivary gland acinar cells, and exocrine pancreatic acinar cells. Ultrastructurally, these vacuoles were consistent with dilated rough endoplasmic reticulum, which sometimes contained homogeneously stained, moderately electron-dense material. The vacuoles in thyroid follicular cells contained pale eosinophilic colloidlike material consistent with accumulated thyroglobulin, as shown by immunohistochemical staining methods. The biological functions of these organs were not adversely affected as evidenced by the absence of clinical signs and the results of selected hormonal analyses. The morphologic changes were completely reversed after a 4-wk recovery period. The incidence and severity of histologic changes were decreased after 13 and 26 wk of treatment compared to 4 wk of treatment, indicating an attenuation of the host response or adaptation to the prolonged p-N-butyl-DNJ administration. We believe that morphologic changes in thyroid follicular cells, salivary gland acinar cells, pancreatic acinar cells, and gastric chief cells were the result of nonspecific inhibition of host &alpha;-glucosidase(s) by p-N -butyl-DNJ, causing clinically silent perturbation in host cell glycoprotein processing and/or glycoprotein transport.
INTRODUCTION
The HIV-1 envelope is comprised of 2 subunits of heavily glycosylated proteins (gp41 and gpl20) that are initially synthesized as a 160-kDa precursor protein (gp160) (4, 17, 19, 27) . Glucosidases (I and II) that catalyze the initial &dquo;trimming&dquo; reactions in the processing of these glycoproteins play a significant role in the maturation of gp 160 [reviewed by Ratner, (19) ]. The inhibition of a-glucosidases by compounds such as deoxynojiromycin (DNJ) represents a novel therapeutic approach for the treatment of HIV infections. In vitro and in vivo studies with these compounds have shown their potential to inhibit HIV-1 glycoprotein maturation (16, 21) . N-butyl-deoxynojiromycin (N-butyl-DNJ), an analog of DNJ, is a very active in vitro anti-HIV agent in this series (5, 6, 10, 11, 20, 25) . In addition, N-butyl-DNJ has been shown to inhibit hepatitis B virus secretion from infected cells (1) and to offset glucosylceramide accumulation in in vitro models of Gaucher's disease (18) , indicating its possible uses for other disease conditions.
Limited information is available about the safety profile of DNJ and its analogs. The N-butyl-DNJ (SC-48334) given in combination with zidovudine to HIV patients has been associated with diarrhea, abdominal pain, and weight loss (5) . Castanospermine, an indolizidine alkaloid isolated from the seeds of the Morton Bay chestnut tree (Castanospermum australae), is structurally similar to DNJ. It also inhibits certain glucosidases (26) and has antiretroviral activity (23, 24) . The administration of castanospermine to rats has been associated with the appearance of cytoplasmic vacuoles in kidney, thyroid gland, skeletal muscle, and liver (28) .
Perbutylated-N-butyl-DNJ (SC-49483) is a perbutylated derivative of N-butyl-l-DNJ (SC-48334) that specifically inhibits a-glucosidase-1 and is a candidate anti-HIV agent targeted against viral glycoprotein processing in host cell endoplasmic reticulum. This perbutylated deriv-ative serves as a prodrug, avoiding the gastrointestinal side effects with metabolism to the DNJ active moiety (SC-48334) for systemic actions. In the present studies, we evaluated the toxicologic effects of p-N-butyl-DNJ in Sprague-Dawley rats after 4, 13, or 26 wk of oral administration. The administration of p-N-butyl-DNJ caused characteristic cytoplasmic vacuolar changes in the thyroid follicular epithelium, pancreatic and salivary gland acinar cells, and gastric chief cells.
MATERIALS AND METHODS
Animals. Charles River Crl:CD(SD)BR rats (Portage, MI) were used in these studies. Rats were approximately 6 wk old at the initiation of studies. They were housed individually in suspended stainless-steel cages and maintained in an environment with controlled temperature (22 ± 1.5°C) and humidity (40% or greater) and 12/12 hr light/dark cycle. The rats were given Purina Rodent Chow (Purina Mills Inc., Richmond, IN) and tap water ad libitum. Animals were randomly assigned to groups using a blocking procedure, with blocks defined from stratified pretreatment body weights.
Compound. Perbutylated-N-butyl-DNJ (SC-49483) is a perbutylated derivative of N-butyl-1-DNJ (SC-48334) metabolized at intestinal absorption to SC-48334 and specifically inhibits the oc-glucosidase-1. Perbutylated-N-butyl-DNJ was given as a suspension in vehicle containing 0.5% methylcellulose and 0.1% polysorbate 80 in distilled water. The control animals received an equivalent volume of vehicle. The compound/vehicle was given by oral gavage in 3 evenly divided dosages per day at approximately 8-hr intervals.
The compound was given to rats for 4, 13, or 26 wk. In the first study (4-wk study, conducted at G. D. Searle & Co., Skokie, IL), 4 groups (15 animals/sex/group) of rats were given p-N-butyl-DNJ at dose levels of 0 (vehicle control), 330, 1,020, and 3,670 mg/kg/day. In this study, 5 animals/sex/group were sacrificed on day 3 and 10 animals/sex/group after 4 wk of dosing. In the second study (26-wk study, conducted at Hazleton Laboratories, Madison, WI), 4 groups (30 animals/sex/group) of rats were given p-N-butyl-DNJ at dose levels of 0 (vehicle control), 300, 600, and 1,200 mg/kg/day. In this study, 5 animals/sex/group were sacrificed at an interim period of 13 wk, 15 animals/sex/group were sacrificed at 26 wk, and 10 animals/sex/group were sacrificed after a 4-wk recovery period.
Histological Examinations. For histological evaluations, specimens from all major organs were collected at necropsy, preserved in 10% buffered formalin, embedded in paraffin, sectioned at 5 /-1m, and stained with hematoxylin and eosin. Histologic evaluations were performed on all major organs including adrenals, pituitary, thyroids, parathyroids, pancreas, Harderian glands, salivary glands, heart, aorta, skeletal muscle, bone, bone marrow, spleen, lymph nodes, brain, spinal cord, tongue, esophagus, stomach, intestines, lungs, liver, kidneys, reproductive organs, and eyes.
In addition, other routine toxicologic endpoints, including clinical signs, body weights, body weight gains, food consumption, organ weights, and clinical pathology parameters, were evaluated in this study (data not shown except for terminal body weights). Hormone Analysis. To determine effects of p-N-butyl-DNJ on endocrine functions, blood samples were collected from each animal in the second study (26-wk study) at the scheduled sacrifices of 13 wk (n = 5 rats/ sex/group), 26 wk (n = 15 rats/sex/group), and 31 wk (5 animals/sex from control and high-dose groups) of study for selected hormonal analyses. Blood samples were collected from posterior vena cava of animals anesthetized with sodium pentobarbital and were stored on wet ice until centrifugation. Serum was harvested and stored at -70°C until analyzed. The hormonal analyses, including thyroid-stimulating hormone (TSH), thyroxine (T4), and triiodothyronine (T 3)' were performed at Hazleton Laboratories (Vienna, VA) using standard radioimmunoassays.
Immunohistochemical Methods. To characterize the cytoplasmic vacuolar contents, formalin-fixed paraffinembedded thyroids were processed for immunohistochemical staining of thyroglobulin. Briefly, consecutive sections of thyroid glands were incubated with either monoclonal mouse anti-human thyroglobulin antibodies (isotype IgGl, Dako Labs, Carpinteria, CA) or irrelevant antibodies as a negative control (mouse IgGl, Dako Labs). Anti-thyroglobulin and control antibodies were used at equivalent protein concentrations, as determined by serial dilution labeling studies. Sections were deparaffinized with xylene, rehydrated with graded alcohols, immersed in distilled water, and then incubated with 0.1 % w/v trypsin solution in 150 mM of Tris, pH 7.6 (Immunon-Trypsin Type II/buffer concentrate) to unmask tissue antigens. Hydrogen peroxide with normal horse serum (Vector Laboratories, Burlingame, CA) was used to block endogenous peroxidase activity, prior to primary antibody labeling. Tissues were incubated with primary (anti-thyroglobulin or negative control) antibodies overnight at 40°C. Biotinylated horse anti-mouse IgG (Vector Laboratories) was used as a secondary antibody. The remaining immunocytochemical reagents were also commercially acquired and contained avidin DH and biotinylated horseradish peroxidase H substrate (Vectastain ABC Elite Kit, Vector Laboratories) and 3',3-diaminobenzidine substrate (DAB substrate Kit, Vector Laboratories). The sections were counterstained with Harris's hematoxylin. Electron Microscopy. To characterize the cytoplasmic changes at subcellular levels, thyroid glands and pancreas from selected animals were processed for transmission electron microscopy. Briefly, thyroid glands and pancreas from selected animals were fixed in half-strength Karnovsky's fixative in 100 mM cacodylate buffer for 2 hr at room temperature (22°C), rinsed, and stored under refrigeration in 100 mM cacodylate buffer. The samples were postfixed in cacodylate-buffered 1 % osmium tetroxide, washed, and embedded in a flat embedding mold. (2) was performed to detect possible differences among standard deviations, and results were reported when significant at the 5% level. The statistical tests for means consisted of a 1-way analysis of variance (31) followed by Student's t-test when the F-ratio detected significant differences at the 5 % level.
RESULTS
Pharmacokinetics analyses indicated that p-N-butyl-DNJ was biologically available, and a dose-dependent increase in plasma concentrations was achieved in all treated groups of Sprague-Dawley rats (data not shown). No compound-related mortality or biologically significant effect on growth and development and clinical signs or gross morphologic changes were noted after 4, 13, and 26 wk of p-N-butyl-DNJ administration. Only slight decreases in body weights (Table I ) and food consumption (data not shown) were seen in high-dose groups.
Light Microscopy
Histologic changes associated with p-N-butyl-DNJ were observed in thyroid gland, stomach, salivary gland, and pancreas after 4, 13, and 26 wk of treatment. These changes were dose-related in incidence and severity and were observed at 330, 1,020, and 3,670 mg/kg/day after 4 wk and at 1,200 mg/kg/day after 26 wk of p-N-butyl-DNJ administration. No histologic changes were observed in these tissues in control animals or in treated animals after 3 days of p-N-butyl-DNJ administration at any dosage level. The no adverse effect dose level of p-Nbutyl-DNJ determined in the 26-wk study was 600 mg/kg/day.
Morphologically, the follicular cells in thyroid glands, chief cells in the gastric mucosa, and acinar cells in salivary gland and pancreas were moderately enlarged (hypertrophied) due to expansion of cytoplasm by variablesized clear or lightly eosinophilic vacuoles ( Figs. 1-4 ). The vacuoles in thyroid follicular cells were sometimes distended with homogeneous pale eosinophilic material resembling colloid. The vacuoles were usually present throughout the cytoplasm in these organs except pancre-as. In pancreas, the cytoplasmic vacuoles were present at the interface of perinuclear basophilic cytoplasm and zymogen granules. The cytoplasmic vacuolation ranged from involvement of a few cells multifocally to a diffuse change with involvement of entire thyroid gland, salivary gland, or pancreas. Similarly, the involvement of gastric chief cells was multifocal to diffuse, especially in animals given 3,670 mg/kg/day p-N-butyl-DNJ. The lumina of affected thyroid follicles appeared smaller than normal due to the enlarged and vacuolated follicular cells. No necrosis or inflammation was associated with these changes. Table II shows the incidence of histologic changes in thyroid gland, stomach, pancreas, and salivary gland after 4 wk of p-N-butyl-DNJ administration. There was no apparent sex predilection for changes in pancreas, stomach, and thyroid gland. However, histologic changes in salivary gland were observed only in males. The incidence of p-N-butyl-DNJ-related changes in thyroid gland, pancreas, salivary gland, and stomach varied from 40 to 70% or 70 to 100% in rats given 1,020 or 3,670 mg/kg/day p-N-butyl-DNJ, respectively. The incidence and severity of histologic lesions in animals after 13 and 26 wk of treatment at similar dosage levels were lower compared to 4 wk of treatment, indicating an attenuation of host response to the prolonged p-N-butyl-DNJ administration. The incidence of histologic lesions after 13 and 26 wk of treatment was lower in females than in males. The morphologic changes in rats after 13 wk of p-N-butyl-DNJ treatment were observed in thyroid glands of 40% of the males and in stomach of 20% of the males and 20% of the females and after 26 weeks in thyroid glands of 27% of the males, in stomach of 13% of the males, and in pancreas of 7% of the males given 1,200 mg/kg of p-N-butyl-DNJ. The animals that received 26 wk of treatment and then had a 4-wk recovery period did not show p-N-butyl-DNJ-related changes.
Additional studies were performed to characterize further the thyroid changes by immunohistochemical methods to identify the contents of follicular cell cytoplasm and by transmission electron microscopy of thyroids and pancreas to demonstrate the subcellular location and morphology of cytoplasmic vacuoles. In addition, biochemical analysis of thyroid-related hormones was performed to demonstrate the potential functional correlates of the morphologic findings.
Immunohistochemistry
The thyroids from p-N-butyl-DNJ-treated animals revealed extensive immunolabeling for thyroglobulin within the cytoplasmic vacuoles of affected follicular epithelium (Fig. 5a ), indicating marked accumulation of thyroglobulin. The staining intensity of thyroglobulin within follicular cell cytoplasm of control animals, in comparison, was more diffuse, finely granular, and less dense (Fig. 5b) . Some thyroglobulin-containing vacuoles (Fig.  5a ) also had clear centers that lacked immunostaining for thyroglobulins.
Electron Microscopy
The ultrastructural evaluation of affected thyroid follicular cells and pancreatic acinar cells exhibited mark-FIGS. 1-4.-Photomicrograph of thyroid (1) , salivary gland (2) , stomach (3), and pancreas (4) from animals orally administered N butyl-DNJ at 3,670 mg/kg/day. Note moderately enlarged cells with cytoplasmic vacuolation (arrowheads) and displaced nuclei in thyroid follicular cells, salivary gland and pancreatic acinar cells, and gastric chief cells. H&E. X 100. edly distended rough endoplasmic reticulum and numerous pleomorphic apically situated membrane bound vacuoles consistent with Golgi apparatus and/or lysosomes (Figs. 6 and 7). The distended rough endoplasmic reticulum and vacuoles sometimes contained homogeneously stained, moderately electron dense material.
Hormonal Analysis
The hormone data are shown in Table III . A slight, statistically significant decrease in T4 levels was observed in male rats following 13 wk of p-N-butyl-DNJ treatment in 600-and 1,200-mg/kg/day groups and following 26 wk of p-N-butyl-DNJ treatment in 300, 600, and 1,200 Abbreviations: M = male; F = female. a n = 10 per group. mg/kg/day groups (p ~ 0.05). Although slightly lower T3 levels in male rats treated with N-butyl-DNJ were observed at both time intervals, the change was statistically significant only at 26 wk in animals given 1, 200 mg/kg/ day p-N-butyl-DNJ (p ~ 0.05). There were no significant changes in T4 and T3 levels in female rats at any time interval. TSH levels were not significantly affected in either sex at any time interval. The changes in T4 and T3 levels were not seen after the 4-wk recovery period. These slight changes in thyroid hormone levels were not considered as an effect of N-butyl-DNJ on thyroid functions because these changes were not dose-dependent and were also present in low-dose groups, which did not have any vacuolar change in the thyroid follicular cells. In addition, there was no clinical evidence of alterations in thyroid function in these animals.
DISCUSSION
Glucosidases catalyze the initial &dquo;trimming&dquo; reactions in the processing of glycoproteins and play a significant role in the maturation of HIV envelope proteins (19) . DNJ and its analogs, including p-N-butyl-DNJ, represent a novel therapeutic approach in the treatment of HIV infections through their inhibition of glucosidases I and II (6, 11, 16, 21) . The present studies describe the morphologic and functional changes associated with p-N butyl- for TSH, T4, and T3 determinations, serum samples were obtained from 3-5 animals/sex after 13 wk and from 13-15 animals/sex after 26 wk of DNJ treatment.
Results represent means ± SD from 3-5 animals/sex at 13 wk and from 13-15 animals/sex at 26 wk. * Statistically significant difference from control at p S 0.05. DNJ in Sprague-Dawley rats after 4, 13, or 26 wk of oral administration at exaggerated dose levels. The prominent histologic changes included characteristic vacuolization in the cytoplasm of thyroid follicular epithelium, pancreatic and salivary gland acinar cells, and gastric chief cells without significant adverse influence on systemic health. The incidence of these histologic lesions decreased after 13 or 26 wk of treatment compared to 4 wk of treatment, indicating an attenuation of host response or adaptation to the prolonged p-N-butyl-DNJ administration. Treatment-related histologic changes were not observed in other tissues.
Castanospermine, an indolizidine alkaloid from the seeds of the Morton Bay chestnut tree (Castanospermum australae) also inhibits a-glucosidases (22, 26) and is structurally similar to p-N-butyl-DNJ. Recently, it was shown that rats administered castanospermine develop vacuolar changes in thyroid follicular epithelium similar to those associated with p-N-butyl-DNJ. However, vacuolar changes in hepatocytes and skeletal myocytes seen with castanospermine (28) were not observed in rats administered p-N-butyl-DNJ. Swainsonine, an inhibitor of a-mannosidase, has also been shown to induce vacuolar changes in many tissues similar to castanospermine (28) . The pancreatic acinar cell vacuolation seen in swainsonine-treated rats is morphologically identical at the light microscopic level to the vacuolar change seen in the pancreas of rats treated with p-N-butyl-DNJ in this study.
Humans with genetic glycogenosis Type II or Pompe's disease lack 1,4,a-glucosidase (8) and exhibit generalized vacuolar cytoplasmic changes involving many different organ systems (3, 8) . However, vacuolar myopathy and vacuolar degeneration of hepatocytes, macrophage phagocytic cells, and neurons, which are typical of Pompe's disease, were not seen in p-N-butyl-DNJ-treated rats. Acarbose, an a-glucosidase inhibitor (Bay g 5421, a pseudotetrasaccharide), has been shown to induce histologic changes in rats similar to Pompe's disease (13) . However, the histologic changes in thyroids, salivary gland, pancreas, and stomach as seen in p-N-butyl-DNJ have not been described with acarbose. These studies suggest that histologic changes with p-N-butyl-DNJ resemble those described with castanospermine, swainson-ine, acarbose, and Pompe's disease but are of lesser severity and involve only a limited number of tissues.
The similarity of vacuolar changes associated with DNJ with those of castanospermine, swainsonine, Acarbose, and Pompe's disease suggests that these changes are likely due to the decreased activity of glucosidases and/or mannosidases in the affected cells. This possibility is further strengthened by the results of in vitro studies showing the inhibitory effects of DNJ on the biosynthesis of several well-defined secretory and membrane glycoproteins (7, 12) . DNJ treatment has been associated with the inhibition of the quantity and rate of secretion of a-antitrypsin and a-antichymotrypsin (12) . Previously reported side effects of diarrhea and flatulence in humans given N-butyl-DNJ (SC-48334) (5) were also possibly associated with inhibition of intestinal glycosidases, such as maltase and sucrase, as has been reported for castanospermine (26) in animal studies.
The morphologic characteristics of cytoplasmic alterations in affected tissues suggested involvement of a similar mechanism responsible for the changes in all affected organs. The ultrastructural features of vacuoles in thyroid follicular and pancreatic acinar cells in this study were consistent with dilated rough endoplasmic reticulum and numerous scattered anomalous vacuoles representing the Golgi apparatus and lysosomes. Similar subcellular vacuoles in the rough endoplasmic reticulum of pancreatic acinar cells in swainsonine-treated guinea pigs and in hepatocytes of castanospermine-treated calves have been previously reported (9, 14) .
The immunohistochemical evaluations for thyroglobulins in thyroid glands of p-N-butyl-DNJ-treated rats revealed vacuoles containing the qualitatively increased labeling intensity of thyroglobulin. Similar accumulation of a-1-antitrypsin and a-1-antichymotrypsin in rough endoplasmic reticulum of DNJ-treated hepatoma Hep G2 cells has been reported in in vitro studies using endo-Hsensitivity and equilibrium gradient centrifugation methods (12) . The lectin histochemistry of vacuoles in swainsonine-and castanospermine-treated rats indicated an accumulation of incompletely metabolized oligosaccharides rich in N-acetyl-glucosamine and a-mannose residues in the affected cells (28) . The oligosaccharide banding pat-tern analysis of purified thyroglobulins from thyroid follicular epithelium of p-N-butyl-DNJ-treated rats also showed accumulation of high molecular weight bands consistent with precursor thyroglobulins (Dr. Pat Manos, personal communications). These results further support the notion that p-N-butyl-DNJ inhibits host a-glucosidases, resulting in altered glycoprotein processing and accumulation of incompletely metabolized oligosaccharides in rough endoplasmic reticulum of affected cells. However, the process at modest exposure exaggerations achieves a steady state without significantly impacting growth and development, suggesting accommodation.
In this study, the serum T4 and T3 levels were slightly lower in p-N-butyl-DNJ-treated rats compared with control rats. These slight changes in thyroid hormone levels were not considered as an effect of N-butyl-DNJ on thyroid functions because these changes were not dose-dependent and were also present in low-dose groups, which did not have any vacuolar change in the thyroid follicular cells. In addition, there was no clinical evidence of alterations in thyroid function and changes in cholesterol and erythroid parameters commonly associated with hypothyroidism. It is possible that slight decreases in T4 and T3 levels in the p-N-butyl-DNJ-treated animals was associated with a slight decrease in food consumption and body weight gains seen in this study. The decrease in thyroid hormone levels due to a decrease in food consumption and body weight gains have been reported in several animal species (15, 29) .
The vacuolar change was not seen in the p-N-butyl-DNJ-treated rats after a 4-wk recovery period, suggesting complete reversibility of this change. A similar response has been shown in in vitro experiments (12) , in which removal of DNJ from the cultures restored normal secretion of a-antitrypsin, indicating that its inhibitory effect is not only accommodated but also reversible. The preceding vacuolar changes are most consistent with a nonspecific pharmacologic effect of p-N-butyl-DNJ on inhibition of host a-glucosidases resulting in aberrant glycoprotein processing and intra-extracellular translocation. The accommodation of vacuolar change and lack of its progression with prolonged p-N-butyl-DNJ treatment is probably due to its specificity for a-glucosidase-1 only and the involvement of alternate &dquo;salvage&dquo; pathways for protein processing.
In conclusion, p-N-butyl-DNJ treatment of rats resulted in characteristic vacuolar change in the cytoplasm of thyroid follicular epithelium, pancreatic and salivary gland acinar cells, and gastric chief cells, which are maximal early in the treatment and completely reversible after cessation of treatment. The cytoplasmic vacuolar change was predominantly due to dilated rough endoplasmic reticulum as a result of accumulation of incompletely processed cellular glycoproteins. These changes appear to be secondary to p-N-butyl-DNJ inhibition of host a-glucosidases. There were no clinical signs or biologically significant changes in growth and development attributable to these findings. These results suggest that host cells are able to maintain functions within normal limits even with prolonged exposure to the compound due to metabolic accommodation over time.
